Want to see HK:1110 full AI Analyst Report?
Kingworld Medicines Group Ltd. (1110) AI Stock Analysis
Top Page
Kingworld Medicines Group Ltd.
(HKEX:1110)
The score is held back mainly by weakening financial performance (revenue decline and sharply lower margins) and bearish technical signals (below key moving averages with negative MACD). Valuation provides partial support through a high dividend yield, but the P/E is only moderate and does not fully offset the fundamental and trend pressures.
Kingworld Medicines Group Ltd. (1110) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 221.18M
- Dividend Yield
- 8.45%
- Average Volume (3M)
- 2.01M
- Price to Earnings (P/E)
- 16.8
- Beta (1Y)
- 0.18
- Revenue Growth
- -13.82%
- EPS Growth
- 112.24%
- Country
- Hong Kong
- Employees
- 711
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Kingworld Medicines Group Ltd. Business Overview & Revenue Model
Company Description
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and gene...
How the Company Makes Money
Kingworld Medicines Group Ltd. primarily makes money by selling pharmaceutical and healthcare products through wholesale/distribution and related sales activities. Key revenue streams typically include: (1) distribution/wholesale revenue from purchas...
Kingworld Medicines Group Ltd. Financial Statement Overview
Summary
Financial performance is stable but weakening. Revenue turned down in 2024 and fell more meaningfully in 2025, while profitability deteriorated sharply (net margin ~1.2% in 2025 vs ~3.9% in 2024). Gross margin held in the mid-to-high 20% range, but rising leverage (debt-to-equity ~0.70 in 2025 vs ~0.39 in 2021) and compressed ROE (~1.8% in 2025) add risk. Cash flow remains positive, but operating and free cash flow have been volatile, reducing confidence in durability.
Income Statement
46NeutralBalance Sheet
58NeutralCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 787.87M | 917.34M | 1.06B | 1.08B | 957.70M | 847.39M |
| Gross Profit | 240.04M | 247.91M | 270.45M | 280.67M | 277.63M | 263.60M |
| EBITDA | 80.78M | 82.70M | 110.77M | 125.48M | 118.07M | 116.00M |
| Net Income | 11.47M | 11.28M | 41.56M | 38.10M | 22.74M | 30.32M |
Balance Sheet | ||||||
| Total Assets | 1.30B | 1.44B | 1.42B | 1.34B | 1.26B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 188.35M | 274.70M | 249.60M | 194.03M | 256.17M | 198.41M |
| Total Debt | 438.04M | 434.05M | 402.44M | 354.43M | 290.68M | 238.96M |
| Total Liabilities | 648.92M | 753.86M | 710.04M | 638.30M | 569.15M | 493.19M |
| Stockholders Equity | 596.45M | 617.97M | 639.79M | 619.03M | 615.58M | 616.90M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | 54.92M | 94.73M | -63.25M | 93.64M | 22.88M |
| Operating Cash Flow | 38.39M | 84.56M | 135.82M | 42.28M | 186.55M | 81.20M |
| Investing Cash Flow | -15.51M | -20.11M | -27.64M | -120.63M | -84.05M | -50.84M |
| Financing Cash Flow | -60.57M | -30.82M | -47.61M | 4.37M | -51.31M | -87.20M |
Kingworld Medicines Group Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1110, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.39, and below the 200-day MA of 0.45, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 47.75 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1110.
Kingworld Medicines Group Ltd. Peers Comparison
Overall Rating
HK:023977Outperform
HK:089758.6Neutral
HK:085854Neutral- HK:111051Neutral
HK:045544Neutral
HK:149842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 77Outperform | HKD 774.43M | 7.76 | 13.59% | 7.44% | 10.63% | 39.44% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0858 | 54Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1110 | 51Neutral | HKD 227.44M | 16.84 | 1.89% | 8.45% | -13.82% | 112.24% |
| HK:0455 | 44Neutral | HKD 191.35M | -2.73 | -14.55% | ― | 12.89% | -2.56% |
| HK:1498 | 42Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1110 | Kingworld Medicines Group Ltd. | 0.38 | -0.16 | -29.25% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:0455 | Tianda Pharmaceuticals Ltd. | 0.09 | -0.05 | -34.07% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.48 | 0.25 | 11.09% |
Kingworld Medicines Group Ltd. Corporate Events
Kingworld Medicines Narrows Shareholder Loss Despite Sharp Revenue Decline
Kingworld Medicines Group Ltd., a pharmaceutical and healthcare products distributor in mainland China with supplementary income from investment properties and equity interests, reported mixed interim results for the six months ended 30 June 2026. Th...
Kingworld Medicines Schedules Board Meeting to Review Interim Results and Dividend
Kingworld Medicines Group Ltd. has announced that its board of directors will convene on 27 August 2026 in Hong Kong to review and approve the unaudited interim results for the six months ended 30 June 2026. The meeting will also consider the recomme...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026